Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Gastrointestinal Bleeding Common Following Angioplasty for MI

By HospiMedica International staff writers
Posted on 26 Oct 2011
Patients with acute myocardial infarction (AMI) who undergo primary percutaneous coronary intervention (PCI) and antiplatelet therapy suffer a high incidence of upper gastrointestinal (GI) bleeding, according to a new study.

Researchers at Kaohsiung Chang Gung Memorial Hospital (Taiwan) conducted a prospective study involving 1,368 consecutive patients between May 2002 and September 2010 who experienced ST-segment elevation myocardial infarction (STEMI) and underwent subsequent primary PCI. More...
The researchers wished to investigate the incidence of composite major adverse upper gastrointestinal (UGI) events (MAUGIEs) in patients with acute STEMI who underwent primary PCI and routinely received dual-antiplatelet therapy. For the study, MAUGIEs were defined as gastric ulcer, duodenal ulcer, gastroduodenal ulcer, or UGI bleeding.

The results showed that about one quarter of patients who developed MAUGIEs in the hospital died before discharge, compared to only 10.4% of patients who had no major upper GI events. The investigators also reported that 16% of the patients who suffered MAGUIEs in the hospital developed recurrent major upper GI events during an average follow-up of about 3.3 years; the vast majority of these patients (97%) received long-term clopidogrel. Age, advanced Killip score, and respiratory failure were all significantly and independently predictive of in-hospital composite MAUGIEs. The study was published early online on September 19, 2011, in the American Journal of Cardiology.

“Prophylaxis against upper GI bleeding with a proton pump inhibitor is indicated for patients hospitalized for AMI, particularly those of advanced Killip classes,” said lead author Hon-Kan Yip, MD. “Since a PPI is known to interact with the antiplatelet agent clopidogrel resulting in an elevated risk of intra-coronary thrombosis, an interval of at least four hours is suggested between the administrations of these agents”

The Killip classification stratifies AMI patients; individuals with a low Killip class are less likely to die within the first 30 days after MI than individuals with a high Killip class. Killip class I includes individuals with no clinical signs of heart failure; class II includes individuals with rales or crackles in the lungs, and elevated jugular venous pressure; class III describes individuals with frank acute pulmonary edema; and class IV describes individuals in cardiogenic shock or hypotension, and evidence of peripheral vasoconstriction (oliguria, cyanosis, or sweating).

Related Links:
Kaohsiung Chang Gung Memorial Hospital



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hypodermic Syringe
SurTract™ Safety Syringe
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.